KEGG   DRUG: Zolbetuximab
Entry
D11527                      Drug                                   
Name
Zolbetuximab (USAN/INN);
Zolbetuximab (genetical recombination) (JAN);
Vyloy (TN)
Product
Formula
C6534H10066N1726O2056S44
Exact mass
147014.3881
Mol weight
147105.10
Sequence
(Heavy chain)
QVQLQQPGAE LVRPGASVKL SCKASGYTFT SYWINWVKQR PGQGLEWIGN IYPSDSYTNY
NQKFKDKATL TVDKSSSTAY MQLSSPTSED SAVYYCTRSW RGNSFDYWGQ GTTLTVSSAS
TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL
YSLSSVVTVP SSSLGTQTYI CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC PAPELLGGPS
VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSREEMT
KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQ
GNVFSCSVMH EALHNHYTQK SLSLSPGK
(Light chain)
DIVMTQSPSS LTVTAGEKVT MSCKSSQSLL NSGNQKNYLT WYQQKPGQPP KLLIYWASTR
ESGVPDRFTG SGSGTDFTLT ISSVQAEDLA VYYCQNDYSY PFTFGSGTKL EIKRTVAAPS
VFIFPPSDEQ LKSGTASVVC LLNNFYPREA KVQWKVDNAL QSGNSQESVT EQDSKDSTYS
LSSTLTLSKA DYEKHKVYAC EVTHQGLSSP VTKSFNRGEC
(Disulfide bridge: H22-H96, H145-H201, H221-L220, H227-H'227, H230-H'230, H262-H322, H368-H426, H'22-H'96, H'145-H'201, H'221-L'220, H'262-H'322, H'368-H'426, L23-L94, L140-L200, L'23-L'94, L'140-L'200)
  Type
Peptide
Remark
Therapeutic category: 4291
ATC code: L01FX31
Product: D11527<JP/US>
Efficacy
Antineoplastic, Anti-claudin 18.2 antibody
  Disease
Gastric or gastroesophageal junction adenocarcinoma (HER2 negative, claudin 18.2 positive) [DS:H00018]
  Type
Monoclonal antibody
Target
CLDN18 [HSA:51208] [KO:K06087]
  Pathway
hsa04514  Cell adhesion molecules
hsa04530  Tight junction
hsa04670  Leukocyte transendothelial migration
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    L01FX Other monoclonal antibodies and antibody drug conjugates
     L01FX31 Zolbetuximab
      D11527  Zolbetuximab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Antineoplastics
  Molecular Target Inhibitors
   Anti-CLDN18.2 Antibodies
    Zolbetuximab
     D11527  Zolbetuximab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D11527  Zolbetuximab (USAN/INN); Zolbetuximab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   Other
    CLDN18
     D11527  Zolbetuximab (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11527
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D11527
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D11527
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11527
Other DBs
CAS: 1496553-00-4
PubChem: 384585503
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system